» Articles » PMID: 24157031

Long-term Outcome of Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2013 Oct 26
PMID 24157031
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Combined hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) is a rare pair of intrahepatic malignancies. Differential diagnosis among combined HCC-CCC, HCC, or CCC can be difficult; thus malignancies other than ordinary HCC are occasionally encountered unexpectedly in explanted liver specimens. The present study analyzed the long-term outcomes of liver transplantation (OLT) among patients with HCC-CCC.

Methods: Between January 1999 and December 2009, we performed 2137 adult OLT at our institution including 15 cases of pathologically confirmed HCC-CCC, who all underwent OLT with a pretransplant diagnosis of HCC. We reviewed retrospectively the medical records of these 15 patients.

Results: Their mean age was 58.9 ± 7.2 years. The median preoperative alpha-fetoprotein level was 32.6 ng/mL. Fourteen patients underwent living donor and one deceased donor OLT. The Milan criteria were met in 12 cases. A single tumor was identified in 8 and multiple lesions in 7 patients. The maximal tumor diameter was 2.9 ± 1.7 cm. Seven patients experienced tumor recurrences: including 6 within the first 12 months. All of the patients who experienced recurrences died at a median 4 months after that diagnosis. The overall patient survival rates were 66.7% at 1 year and 60.0% at 3 and 5 years. Disease-free patient survival rates were 60.0% at 1 year and 53.3% at 3 and 5 years.

Conclusions: Patients with combined HCC-CCC showed a high rate of early recurrences, particularly within the first year.

Citing Articles

Liver Transplantation for Incidental Cholangiocarcinoma or Combined Hepatocellular Carcinoma/Cholangiocarcinoma-Own Experiences and Review of the Literature.

Schwenk L, Rohland O, Ali-Deeb A, Dondorf F, Settmacher U, Rauchfuss F Cancers (Basel). 2023; 15(14).

PMID: 37509271 PMC: 10377009. DOI: 10.3390/cancers15143609.


Radiomics Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma from Hepatocellular Carcinoma: A Multi-Center Study.

Guo L, Li X, Zhang C, Xu Y, Han L, Zhang L J Hepatocell Carcinoma. 2023; 10:795-806.

PMID: 37288140 PMC: 10243611. DOI: 10.2147/JHC.S406648.


Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Yang J, Roberts L Curr Hepatol Rep. 2022; 17(4):385-391.

PMID: 35990187 PMC: 9387765. DOI: 10.1007/s11901-018-0431-9.


Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.

Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi A Cancers (Basel). 2021; 13(13).

PMID: 34283065 PMC: 8268054. DOI: 10.3390/cancers13133336.


Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma.

Azizi A, Hadjinicolaou A, Goncalves C, Duckworth A, Basu B Front Oncol. 2020; 10:570958.

PMID: 33102226 PMC: 7545907. DOI: 10.3389/fonc.2020.570958.